To counter such impacts, some companies are exploring ways that GLP-1RA drugs could complement their existing solutions

Compounded semaglutide may be a reasonable option for: Patients who do not have insurance coverage for brand-name semaglutide and do not qualify for manufacturer assistance programs Patients working with a physician who is actively monitoring them baseline metabolic labs, regular follow-up, dose adjustment based on response and tolerability Patients sourcing from a verified 503B outsourcing facility using semaglutide base (not a salt form) Patients who have been counseled on proper injection technique and the specific concentration of their formulation Patients who should be cautious: Patients using telehealth platforms that do not require baseline labs or follow-up visits a prescriber who will send semaglutide to anyone who completes an online questionnaire is not providing adequate clinical oversight Patients whose compounded formulation contains additional ingredients (B12, L-carnitine, etc.) without a clear clinical rationale for the supplements that do have evidence behind them on GLP1 therapy, and the doses that actually matter, see our GLP1 Support Protocol Patients who are self-adjusting doses without clinical guidance Patients who should avoid compounded semaglutide: Anyone sourcing from a compounder who cannot verify their 503A or 503B status and provide a Certificate of Analysis for potency and sterility testing Patients with a history of medullary thyroid carcinoma medullary thyroid carcinoma (MTC) A rare cancer of the thyroids hormone-producing C-cells

What does this mean for the future of GLP-1 treatment
Experimental studies in animals provide additional insight: GLP-1 analogs increased testosterone synthesis and improved sperm mitochondrial integrity in diabetic and obese models
Oral medications should be administered at least 1 hour prior to Symlin injection or 2 hours after Symlin injection Drugs Affecting Gastrointestinal Motility: Due to its effects on gastric emptying, Symlin should not be considered for patients taking medications that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) or medications that slow the intestinal absorption of nutrients (e.g., alpha-glucosidase inhibitors)